Consolidated revenue growth 15-21% for FY26
Management reaffirmed the earlier guidance despite Q1 growth of 7.4%, citing ramp-down of trade generics as a temporary drag.
ERISLIFESCIENCES / guidance tracker
Keep management guidance in view.
Eris Lifesciences · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
Net debt target of ₹1,800 crore by FY26 end
Net debt stood at ₹2,300 crore in Q1; management reaffirmed reduction to ₹1,800 crore by year-end, implying net debt/EBITDA of ~1.5x.
Insulin cartridge production to commence in Q4 FY26
Manufacturing of insulin cartridges at Bopal expected to start in Q4, with market opportunity from Novo Nordisk's exit accruing from Nov-Dec 2025.
International business to reach ₹1,000 crore by FY28-29
Includes CDMO, RO business, OSD exports, and B2C; CDMO commercialization expected from FY27 with ₹100 crore+ confirmed contracts.